dexamethasone 21-phosphate has been researched along with aprepitant in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, MR; Jiles, C; Seibel, NL | 1 |
| Duersch, B; Placek, J; Schaller, J; Sun, S | 1 |
2 other study(ies) available for dexamethasone 21-phosphate and aprepitant
| Article | Year |
|---|---|
Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV).
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Child; Child, Preschool; Dexamethasone; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Morpholines; Nausea; Neoplasms; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting | 2010 |
Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids.
Topics: Antiemetics; Aprepitant; Dexamethasone; Drug Combinations; Drug Incompatibility; Drug Stability; Drug Storage; Glucocorticoids; Glucose; Infusions, Intravenous; Methylprednisolone Hemisuccinate; Morpholines; Serotonin 5-HT3 Receptor Antagonists; Sodium Chloride | 2013 |